Antifolate activity of epigallocatechin gallate against Stenotrophomonas maltophilia

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2914-2920

  Navarro Martínez, María Dolores ^a   Navarro Perán, Enma ^a   Cabezas Herrera, Juan ^b   Ruiz Gómez, Joaquín ^b   García Cánovas, Francisco ^a   Rodríguez López, José Neptuno ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM SULFATE; ANTIINFECTIVE AGENT; CATECHIN; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; EPIGALLOCATECHIN GALLATE; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

AFFINITY CHROMATOGRAPHY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; FOLATE METABOLISM; GEL FILTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STENOTROPHOMONAS MALTOPHILIA; TEA;

ANTI-BACTERIAL AGENTS; CATECHIN; FOLIC ACID ANTAGONISTS; HUMANS; KINETICS; METHOTREXATE; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM; TRIMETHOPRIM RESISTANCE;

EID: 18844431280     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2914-2920.2005     Document Type: Article

References (41)

1. Backus, H. H., H. M. Pinedo, D. Wouters, J. M. Padron, N. Molders, C. L. van Der Wilt, C. J. van Groeningen, G. Jansen, and G. J. Peters. 2000. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer 15:771-778.
2. Barbolla, R., M. Catalano, B. E. Orman, A. Famiglietti, C. Vay, J. Smayevsky, D. Centrón, and S. A. Piñeiro. 2004. Class I integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob. Agents Chemother. 48:666-669.
3. Burns, J. L., D. M. Lien, and L. A. Hedin. 1989. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob. Agents Chemother. 33:1247-1251.
4. Burns, R. L., and L. Lowe. 1997. Xanthomonas maltophilia infection presenting as erythematous nodules. J. Am. Acad. Dermatol. 37:836-838.
5. Clark, N. M., J. Patterson, and J. P. Lynch III. 2003. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr. Opin. Crit. Care 9:413-423.
6. Cornish-Bowden, A. 1979. Fundamentals of enzyme kinetics, p. 34-37. Butterworth and Co., London, United Kingdom.
7. Crum, N. F., G. C. Utz, and M. R. Wallace. 2002. Stenotrophomonas maltophilia endocarditis. Scand. J. Infect. Dis. 34:925-927.
8. Dale, G. E., C. Broger, A. D'Arcy, P. G. Hartman, R. deHoogt, S. Jolidon, I. Kompis, A. M. Lab, H. Langen, M. G. Page, D. Stuber, R. L. Then, B. Wipf, and C. Oefner. 1997. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 266:23-30.
9. de Groot, R., M. Sluijter, A. de Bruyn, J. Campos, W. H. Goessens, A. L. Smith, and P. W. Hermans. 1996. Genetic characterization of trimethoprim resistance in Haemophilus influenzae. Antimicrob. Agents Chemother. 40:2131-2136.
10. Denton, M., and K. G. Kerr. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11:57-80.
11. de Roux, A., and H. Lode. 2003. Recent development in antibiotic treatment. Infect. Dis. Clin. N. Am. 17:739-751.
12. Golicnik, M., and J. Stojan. 2004. Slow-binding inhibition: a theoretical and practical course for students. Biochem. Mol. Biol. Edu. 32:228-235.
13. Gready, J. E. 1980. Dihydrofolate reductase: binding of substrates and inhibitors and catalytic mechanism. Adv. Pharmacol. Chemother. 17:37-102.
14. Heyendael, V. M. R., P. I. Spuls, B. C. Opmeer, C. A. J. M. de Borgie, J. B. Reitsma, W. F. M. Goldschmidt, P. M. M. Bossuyt, J. D. Bos, and M. A. de Rie. 2003. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349:658-665.
15. Hu, Z. Q., W. H. Zhao, N. Asano, Y. Yoda, Y. Hara, and T. Shimamura. 2002. Epigallocatechin gallate synergistically enhances the activity of carbapenems against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:558-560.
16. Hu, Z. Q., W. H. Zhao, Y. Hara, and T. Shimamura. 2001. Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 48:361-364.
17. Huovinen, P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32:1608-1614.
18. Huovinen, P., L. Sundström, G. Swedberg, and O. Sköld. 1995. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
19. Irifune, K., T. Ishida, K. Shimoguchi, J. Ohtake, T. Tanaka, N. Morikawa, M. Kaku, H. Koga, S. Kohno, and K. Hara. 1994. Pneumonia caused by Stenotrophomonas mallophilia with a mucoid phenotype. J. Clin. Microbiol. 32:2856-2857.
20. Jones, R. N. 2001. Resistance patterns among nosocomial pathogens: trends over the past years. Chest 119:397S-404S.
21. Klausner, J. D., C. Zukerman, A. P. Limaye, and L. Corey. 1999. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of hand-washing soap. Infect. Control Hosp. Epidemiol. 20:756-758.
22. Lee, N., K. I. Yuen, and C. R. Kumana. 2003. Clinical role of β-lactam/β-lactamase inhibitor combinations. Drugs 63:1511-1524.
23. Mabe, K., M. Yamada, I. Oguni, and T. Takahashi. 1999. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob. Agents Chemother. 43:1788-1791.
24. Marquardt, D. W. 1963. An algorithm for least-squares estimation of non-linear parameters. J. Soc. Ind. Appl. Math. 11:431-441.
25. Muder, R. R., A. P. Harris, S. Muller, M. Edmond, J. W. Chow, K. Papadakis, M. W. Wagener, G. P. Bodey, and J. M. Steckelberg. 1996. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin. Infect. Dis. 22:508-512.
26. Mukhtar, H., and N. Ahmad. 2000. Tea polyphenols: prevention of cancer and optimizing health. Am. J. Clin. Nutr. 71:1698S-1702S.
27. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS publication M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Navarro-Perán, E., J. Cabezas-Herrera, F. García- Cánovas, M. C. Durrant, R. N. F. Thorneley, and J. N. Rodríguez-López. 2005. The antifolate activity of tea catechins. Cancer Res. 265:2059-2064.
29. Papadakis, K. A., S. E. Vartivarian, M. E. Vassilaki, and E. J. Anaissie. 1997. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J. Neurosurg. 87:106-108.
30. Petri, A., L. Tiszlavicz, E. Nagy, Z. Morvay, E. L. Kokai, G. K. Savanya, and A. Balogh. 2003. Liver abscess caused by Stenotrophomonas maltophilia: report of a case. Surg. Today 33:224-228.
31. Pikis, A., J. A. Donkersloot, W. J. Rodríguez, and J. M. Keith. 1998. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J. Infect. Dis. 178:700-706.
32. Poules, C. D., S. O. Matsumura, B. M. Willey, D. E. Low, and A. McGeer. 1995. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob. Agents Chemother. 39:2220-2223.
33. San Gabriel, P., J. Zhou, S. Tabibi, Y. Chen, M. Trauzzi, and L. Saiman. 2004. Antimicrobial susceptibility and synergy studies of Stenoirophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171.
34. Sevillano, D., S. Valdezate, and M. L. Gómez-Lus. 2001. An update on the susceptibility of Stenotrophomonas maltophilia. Rev. Esp. Quimioter. 14:138-154.
35. Smith, S. L., P. Patrick, D. Stone, A. W. Phillips, and J. J. Burchall. 1979. Porcine liver dihydrofolate reductase: purification, properties, and amino acids sequence. J. Biol. Chem. 254:11475-11484.
36. SPSS, Inc. 2003. Sigma Plot SPSS. SPSS, Chicago, Ill .
37. Stapleton, P. D., S. Shah, J. C. Anderson, Y. Hara, J. M. Hamilton-Miller, and P. W. Taylor. 2004. Modulation of β-lactam resistance in Staphylococcus aureus by catechins and gallates. Int. J. Antimicrob. Agents 23:462-467 .
38. Stone, S. R., and J. F. Morrison. 1986. Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues. Biochim. Biophys. Acta 869:275-285.
39. Vartivarian, S. E., K. A. Papadakis, and E. J. Anaissie. 1996. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch. Intern. Med. 156:433-435.
40. Wilquet, V., J. A. Caspar, M. van de Lande, M. Van de Casteele, C. Legrain, E. M. Meiering, and N. Glansdorff. 1998. Purification and characterization of recombinant Thermotoga maritima dihydrofolate reductase. Eur. J. Biochem. 255:628-637.
41. Yang, C. S. 1997. Inhibition of carcinogenesis by tea. Nature 389:134-135.